Thanks to its selection for a Ministry of Trade, Industry and Energy project, RudaCure Inc. was able to receive support for raw material pharmaceutical production and formulation research for RCI001. In addition, by being selected for the SME Innovation Growth project, the company became able to conduct domestic and international clinical trials.
RCI001, which has been attracting attention as a candidate substance for dry eye disease treatment, demonstrates anti-inflammatory effects by selectively modulating multifunctional signaling molecules. It is also being developed as an eye drop due to its observed improvement in tear secretion function. This new drug candidate is targeting clinical trial entry domestically and internationally next year.
